Meda has acquired exclusive rights to flupirtine for the treatment of fibromyalgia from Adeona Pharmaceuticals, in the U.S., Canada and Japan. Meda will take over full responsibility for development and commercialization of the drug, which is currently in Phase II development for fibromyalgia. Under the agreement, Adeona will receive an up front payment, milestone payments upon FDA acceptance and approval of the NDA, and royalties on sales. “We are very pleased to collaborate with Adeona in t...